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Abstract
Background: ZEB2 has been suggested to mediate EMT and disease aggressiveness in several types of human cancers.
However, the expression patterns of ZEB2 in hepatocellular carcinoma (HCC) and its effect on prognosis of HCC patients
treated with hepatectomy are unclear.
Methodology/Principal Findings: In this study, the methods of tissue microarray and immunohistochemistry (IHC) were
utilized to investigate ZEB2 expression in HCC and peritumoral liver tissue (PLT). Receiver operating characteristic (ROC),
spearman’s rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the
data. Up-regulated expression of cytoplasmic/nuclear ZEB2 protein was observed in the majority of PLTs, when compared to
HCCs. Further analysis showed that overexpression of cytoplasmic ZEB2 in HCCs was inversely correlated with AFP level,
tumor size and differentiation (P,0.05). Also, overexpression of cytoplasmic ZEB2 in PLTs correlated with lower AFP level
(P,0.05). In univariate survival analysis, a significant association between overexpression of cytoplasmic ZEB2 by HCCs/PLTs
and longer patients’ survival was found (P,0.05). Importantly, cytoplasmic ZEB2 expression in PLTs was evaluated as an
independent prognostic factor in multivariate analysis (P,0.05). Consequently, a new clinicopathologic prognostic model
with cytoplasmic ZEB2 expression (including HCCs and PLTs) was constructed. The model could significantly stratify risk
(low, intermediate and high) for overall survival (P=0.002).
Conclusions/Significance: Our findings provide a basis for the concept that cytoplasmic ZEB2 expressed by PLTs can
predict the postoperative survival of patients with HCC. The combined cytoplasmic ZEB2 prognostic model may become a
useful tool for identifying patients with different clinical outcomes.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most prevalent
cancer types, and both the incidence and mortality rates of HCC
have been steadily increasing in recent years [1]. Unfortunately,
the long-term survival of patient with HCC remains unsatisfactory
despite recent advances in surgical techniques and medical
treatment [2]. This poor outcome is primarily related to the high
incidence of recurrence and metastasis [3,4]. Recurrence and/or
metastasis of HCC are mainly intrahepatic, which suggests that
the peritumoral liver tissue may be a favorable soil for the
spreading tumor cells [5]. Biomarkers that could define the
recurrence and metastatic potential of HCC may develop
appropriate therapeutic regimens in the earlier course of this
cancer; however, promising predictors that can be widely used in
clinical settings are substantially limited [6,7,8].
Zinc finger E-box binding homeobox 2 (ZEB2, also known as
SIP1) is a member of ZEB family of transcriptional factors. ZEB2
protein contains a central homeodomain, CtBP-binding and
Smad-interacting domains and two zinc finger clusters each at
either end [9,10]. ZEB2 directly binds proximal E-boxes within
the E-cadherin gene (cdh1) promoter and mediates transcriptional
repression by recruiting corepressor complexes [11]. ZEB2 was
originally identified as a binding partner of R-Smads, and shown
to be part of the TGF-b pathway frequently involved in
tumorigenesis [10]. hTERT repression in breast cancer cells could
be partly mediated by ZEB2 in a TGF-b dependent manner [12].
In clonal HCC cells, ZEB2 was also found to be a mediator of
hTERT repression by analysis of senescence arrest [13]. The
relevance of ZEB2 protein to tumor progression has been studied
in several types of human cancers. High ZEB2/E-cadherin ratio
correlated with the aggressive phenotype and poor patient survival
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were examined in renal cell carcinomas in a hypoxia-inducible
factor 1 alpha-dependent manner [15]. Sayan et al indicated that
overexpression of ZEB2 was an independent prognostic factor in
bladder cancer and positively correlated with poor therapeutic
outcome [16]. In addition, immunohistochemical analysis of oral
squamous cell carcinomas revealed that ZEB2 protein was
detected in a relatively low proportion of tumors and its expression
correlated with poor prognosis [17]. Up to the present, however,
the protein expression state of ZEB2 in HCC and the
clinicopathologic/prognostic significance of this state have not
been explored.
In the current study, immunohistochemistry (IHC) and tissue
microarray were utilized to examine the distribution and
frequency of ZEB2 expression in our HCC and peritumoral liver
tissue (PLT) cohort. In order to avoid predetermined cutpoint,
receiver operating characteristic (ROC) curve analysis was applied
to define the cutoff score for separating ZEB2 overexpressed
tumors from ZEB2 normally expressed tumors. Subsequently, the
clinicopathologic/prognostic significance of ZEB2 expression in
HCCs and PLTs was investigated.
Methods
Ethics statement
The study was approved by the Institute Research Medical
Ethics Committee of Sun Yat-Sen University. No informed
consent (written or verbal) was obtained for use of retrospective
tissue samples from the patients within this study, most of whom
were deceased, since this was not deemed necessary by the Ethics
Committee, who waived the need for consent. All samples were
anonymised.
Patients and tissue specimens
In our study, the paraffin-embedded pathologic specimens from
248 patients with HCC were obtained from the archives of
Department of Pathology, Sun Yat-Sen University Cancer Center,
Guangzhou, China, between 1997 and 2008. The cases selected
were based on distinctive pathologic diagnosis of HCC, undergo-
ing primary and curative resection for tumor without preoperative
anticancer treatment, availability of resection tissue and follow-up
data. These HCC cases included 220 (88.7%) men and 28 (11.3%)
women, with mean age of 47.8 years. Average follow-up time was
31.8 months (median, 26.0 months; range, 1.0 to 86.0 months).
Patients whose cause of death remained unknown or patients
with neoadjuvant and adjuvant therapy were excluded from our
study. Clinicopathologic characteristics for these patients including
age, sex, hepatitis history, alpha-fetoprotein (AFP), liver cirrhosis,
tumor number, size, differentiation, stage, vascular invasion and
relapse were collected and detailed in Table 1. Tumor
differentiation was based on the criteria proposed by Edmonson
and Steiner [18]. Tumor stage was defined according to American
Joint Committee on Cancer/International Union Against Cancer
tumor-node-metastasis (TNM) classification system [19]. In
addition, for ZEB2 western blotting analysis, fresh tissue specimens
from 12 patients with HCC who underwent surgical resection
were collected in 2011. Institute Research Medical Ethics
Committee of Sun Yat-Sen University Cancer Center granted
approval for this study.
Western blotting analysis
Equal amounts of whole tissue lysates were resolved by SDS-
polyacrylamide gel electrophoresis (PAGE) and electrotransferred
on a polyvinylidene difluoride (PVDF) membrane (Pall Corp., Port
Washington, NY). The tissues were then incubated with primary
anti-ZEB2 (Cat. No. HPA003456, Sigma, St. Louis, MO, 1:1000
dilution). The immunoreactive signals were detected with
enhanced chemiluminescence kit (Amersham Biosciences, Up-
psala, Sweden). The procedures followed were conducted in
accordance with the manufacturer’s instructions.
Tissue microarray (TMA) construction
Tissue microarray was constructed as the method described in
our previous study [20]. In brief, formalin-fixed, paraffin-
embedded tissue blocks and the corresponding H&E-stained slides
were overlaid for TMA sampling. The slides were reviewed by a
senior pathologist (M-Y. C.) to determine and mark out
representative tumor areas. Duplicates of 0.6 mm diameter
cylinders were punched from representative tumor areas and
from adjacent non-malignant liver tissue of individual donor tissue
block and re-embedded into a recipient paraffin block at defined
position, using a tissue arraying instrument (Beecher Instruments,
Silver Spring, MD).
Immunohistochemistry (IHC)
The TMA slides were dried overnight at 37uC,deparaffinized in
xylene, rehydrated through graded alcohol, immersed in 3%
hydrogen peroxide for 20 minutes to block endogenous peroxidase
activity, and antigen-retrieved by pressure cooking for 3 minutes
in ethylenediamine tetraacetic acid (EDTA) buffer (pH=8.0).
Then the slides were preincubated with 10% normal goat serum at
room temperature for 30 minutes to reduce nonspecific reaction.
Subsequently, the slides were incubated with rabbit polyclonal
anti-ZEB2 (Cat. No. HPA003456, Sigma, St. Louis, MO, 1:100
dilution) which could recognize only one band corresponding to
ZEB2 molecular weight (i.e., 136 kDa), anti-E-cadherin (Dako,
Glostrup, Denmark, 1:50 dilution) and anti-Vimentin (Dako,
Glostrup, Denmark, 1:200 dilution) for 2 hours at room
temperature, respectively. The slides were sequentially incubated
with a secondary antibody (Envision; Dako, Glostrup, Denmark)
for 1 hour at room temperature, and stained with DAB (3,3-
diaminobenzidine). Finally, the sections were counterstained with
Mayer’s hematoxylin, dehydrated, and mounted. A negative
control was obtained by replacing the primary antibody with
normal rabbit or mouse IgG. Known immunostaining positive
slides were used as positive control.
IHC evaluation
Immunoreactivity for ZEB2 protein was evaluated in semi-
quantitative method as described previously [21]. Each TMA spot
was assigned an intensity score from 0–3 (I0, I1–3) and proportion
of tumor cells for that intensity over the total number of tumor
cells was recorded as 5% increments from a range of 0–100 (P0,
P1–3). A final H score (range 0–300) was achieved by adding the
sum of scores obtained for each intensity and proportion of area
stained (H score=I1XP1+I2XP2+I3XP3).
Selection of cutoff score
ROC curve analysis was utilized to determine cutoff value for
separating tumors with ZEB2 overexpression from tumors with
ZEB2 normal expression by using the 0,1-criterion [22]. At the
ZEB2 score, the sensitivity and specificity for each outcome under
study was plotted, thus generating various ROC curves (Figure 1).
The score was selected as the cutoff value, which was closest to the
point with both maximum sensitivity and specificity. Tumors
designated as ‘‘normal expression’’ for ZEB2 were those with
scores below or equal to the cutoff value, while tumors with
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In order to perform ROC curve analysis, the clinicopathologic
features were dichotomized: AFP level (#20 ng/ml, or .20 ng/
ml), tumor size (#5 cm, or .5 cm), tumor multiplicity (single or
multiple), tumor grade (well-moderately or poorly-undifferentiat-
ed), stage (I+II or III+IV), vascular invasion (absence or presence),
relapse (absence or presence) and survival status (death due to
HCC or censored).
Statistical analysis
Statistical analyses were performed using the SPSS software
program (SPSS Standard version 13.0, SPSS Inc, Chicago, IL).
ROC curve analysis was applied to determine the cutoff value for
ZEB2 overexpression by the 0,1-criterion, and the areas under
curves (AUCs) were calculated. The correlations between ZEB2
expression and other variables were analyzed using Spearman rank
test. The statistical significance of the correlation between ZEB2
expression and disease-specific survival was estimated by the log-
rank test. Multiple Cox proportional hazards regression was carried
out to identify the independent factors which had a significant
impact on patient overall survival. A difference was considered
significant if the P value from a two-tailed test was less than 0.05.
Results
The protein expression levels of ZEB2 in liver tissues by
western blotting analysis
We examined the expression levels of ZEB2 protein in 12
additional pairs of HCC and matched adjacent liver tissues by
Western blotting. The results showed that the ZEB2 antibody used
Table 1. Correlation of ZEB2 expression with clinicopathologic variables.
Cytoplasmic overexpression of ZEB2 (%) Nuclear overexpression of ZEB2 (%)
Variables TT P* PLT P*T T P* PLT P*
Age (years) 0.677 0.707 0.650 0.935
#47.8
{ 123 76 (61.8) 60 (48.8) 8 (6.5) 28 (22.8)
.47.8 125 74 (52.9) 58 (46.4) 10 (8.0) 29 (23.2)
Sex 0.106 0.182 0.980 0.089
Male 220 137 (62.3) 108 (49.1) 16 (7.3) 47 (21.4) (49.1)
Female 28 13 (46.4) 10 (35.7) 2 (7.1) 10 (35.7)
HbsAg 0.362 0.769 0.221 0.873
Positive 216 133 (61.6) 102 (47.2) 14 (6.5) 50 (23.1)
Negative 32 17 (53.1) 16 (50.0) 4 (12.5) 7 (21.9)
AFP (ng/ml) 0.001 0.033 0.099 0.160
#20 119 85 (71.4) 65 (54.6) 12 (10.1) 32 (26.9)
.20 129 65 (50.4) 53 (41.1) 6 (4.7) 25 (19.4)
Liver cirrhosis 0.216 0.740 0.582 0.701
Yes 179 104 (58.1) 84 (46.9) 14 (7.8) 40 (22.3)
No 69 46 (66.7) 34 (49.3) 4 (5.8) 17 (24.6)
Tumor size (cm) 0.049 0.943 0.249 0.180
#5 133 88 (66.2) 63 (47.4) 12 (9.0) 35 (26.3)
.5 115 62 (53.9) 55 (47.8) 6 (5.2) 22 (19.1)
Tumor multiplicity 0.543 0.722 0.161 0.802
Single 140 87 (62.1) 68 (48.6) 13 (9.3) 33 (23.6)
Multiple 108 63 (58.3) 50 (46.3) 5 (4.6) 24 (22.2)
Differentiation 0.000 0.880 0.530 0.220
Well-moderate 148 103 (69.6) 71 (48.0) 12 (8.1) 38 (25.7)
Poor-undifferentiated 100 47 (47.0) 47 (47.0) 6 (6.0) 19 (19.0)
Stage 0.072 0.641 0.442 0.563
I-II 173 111 (64.2) 84 (48.6) 14 (8.1) 38 (22.0)
III -IV 75 39 (52.0) 34 (45.3) 4 (5.3) 19 (25.3)
Vascular invasion 0.148 0.094 0.381 0.341
Absent 170 108 (63.5) 87 (51.2) 14 (8.2) 42 (24.7)
Present 78 42 (53.8) 31 (39.7) 4 (5.1) 15 (19.2)
Relapse 0.356 0.504 0.898 0.359
Absent 148 93 (62.8) 73 (49.3) 11 (7.4) 37 (25.0)
Present 100 57 (57.0) 45 (45.0) 7 (7.0) 20 (20.0)
*Chi-square test;
{Mean age; HbsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein; TT, tumor tissue; PLT, peritumoral liver tissue.
doi:10.1371/journal.pone.0032838.t001
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down-regulated expression of ZEB2 was detected in 9/12 (75.0%)
cases of primary HCC tissues compared to adjacent non-
neoplastic liver tissues (Figure S1).
Expression patterns of ZEB2 in HCC and PLT by
immunohistochemistry
ZEB2 staining was mainly on the cytoplasm (Figure 2A–2C)
and/or nuclei (Figure 2D–2F) of tumor cells or hepatocytes. Most
of the stromal cells were negative staining, though sporadic
positive staining on these cells was also observed. For cytoplasmic
expression, semi-quantitation of HCC and PLT in our cohort
demonstrated a mean ZEB2 staining intensity of 53.4% [SE
(standard error), 3.42%] and 151.1% (SE, 5.15%), respectively
(Wilcoxon exact test, P,0.001, Figure 2G). For nuclear expres-
sion, the mean staining intensity of ZEB2 in HCCs was 5.0% (SE,
1.04%), which was significantly lower than those in PLTs (mean,
17.5%; SE, 3.00%; Wilcoxon exact test, P,0.001, Figure 2H).
Further analysis showed that cytoplasmic expression levels of
ZEB2 in peritumoral liver tissues positively correlated with the
levels in the nuclei (r=0.206, P=0.001) and that there was no
significant correlation between cytoplasmic and nuclear expression
of ZEB2 in tumor tissues (r=0.060, P=0.303).
Selection of cutoff scores for ZEB2 overexpression
To identify a single, optimal cutoff value for overexpression,
ROC curve analysis was employed to determine the cutoff score
for expression of ZEB2 in various patterns. The ROC curves for
each clinicopathologic characteristics clearly show the point on the
curve closest to (0.0, 1.0) which maximizes both sensitivity and
specificity for the outcome as described in our previous study [23].
Tumors with scores above the obtained cutoff value were
considered as ZEB2 overexpression leading to the greatest number
of tumors classified based on clinical outcome presence or absence.
According to ROC curve analysis, H score for cytoplasmic ZEB2
expression in HCC tissues above the cutoff value 70 was defined as
overexpression and the corresponding AUCs were described in
Figure 1. Similarly, tumors designated overexpression for
cytoplasmic ZEB2 in PLT, nuclear ZEB2 in HCC, and nuclear
ZEB2 in PLT were those with scores above the value of 165, 5 and
10, respectively (data not shown).
Correlation between ZEB2 expression and HCC patients’
clinicopathologic characteristics and survival
In HCC tissues, further correlation analysis revealed that
overexpression of cytoplasmic ZEB2 was significantly associated
with serum AFP levels, tumor size and differentiation (P,0.05,
Table 1, Figure 3). Furthermore, Kaplan–Meier analysis estab-
lished that the mean disease-specific survival time for patients with
HCC who overexpressed ZEB2 in cytoplasm was 53.8 months,
compared to 41.8 months for patients with HCC who normally
expressed ZEB2 in cytoplasm (P=0.026, log-rank test, Table 2,
Figure 4A).
In peritumoral liver tissues, cytoplasmic overexpression of ZEB2
was negatively correlated with serum AFP level (P=0.033,
Table 1). Univariate analysis showed that patients with HCC
who overexpressed ZEB2 also exhibited a longer survival time
(mean survival time, 57.6 months) than patients with HCC who
normally expressed ZEB2 (mean, 42.5 months; P=0.001, log-rank
test, Table 2, Figure 4B).
In combined analysis of cytoplasmic ZEB2 expression in HCCs
and PLTs, the group with normal expression of ZEB2 in both
HCC and PLT had the worst survival (mean survival time, 37.8
months), the group with normal expression of ZEB2 in either
Figure 1. Receiver operating characteristic curves were created to determine the cutoff score for overexpression of cytoplasmic
ZEB2 in HCCs. The sensitivity and specificity for each outcome were plotted and the areas under curve (AUCs) were indicated: tumor size (P=0.053),
tumor multiplicity (P=0.286), tumor differentiation (P,0.0001), serum AFP (P,0.0001), stage (P=0.330), vascular invasion (P=0.036), relapse
(P=0.581) and survival status (P=0.091).
doi:10.1371/journal.pone.0032838.g001
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months), and the group with overexpression of ZEB2 in both
HCC and PLT had the best survival (mean survival time, 59.5
months; P=0.002; Figure 4C).
No correlation was found between nuclear expression of ZEB2
and clinicopathologic variables, such as patient’s age, sex, AFP,
cirrhosis, tumor size, tumor multiplicity, tumor differentiation,
stage, vascular invasion and tumor relapse (P.0.05, Table 1). In
univariate analysis, no significant association was demonstrated
between patient survival and nuclear expression of ZEB2 neither
in the tumor tissues nor in PLTs (P.0.05, Table 2).
Independent prognostic factors of HCC
Since variables observed to have a prognostic influence on HCC
patients by univariate analysis may covariate, ZEB2 expression
and those clinicopathologic variables that were significant in
Figure 2. The expression patterns of ZEB2 in HCC and peritumoral liver tissues by IHC. (A) Overexpression of Cytoplasmic ZEB2 was
shown in the peritumoral liver tissues (case 52), in which more than 95% hepetocytes revealed positive staining of ZEB2 in cytoplasm (6100). (B) The
tumor tissues (case 37) demonstrated overexpression of cytoplasmic ZEB2, in which more than 85% of tumor cells showed immunoreactivity of ZEB2
in cytoplasm (6100). (C) Normal expression of ZEB2 was observed in a HCC case (case 52), in which less than 10% of tumor cells showed
immunoreactivity of ZEB2 in cytoplasm (6100). (D) Nuclear overexpression of ZEB2 was shown in the peritumoral liver tissues (case 89), in which
more than 80% hepetocytes revealed positive staining of ZEB2 in nuclei (6100). (E) The tumor tissues (case 76) demonstrated overexpression of
nuclear ZEB2, in which more than 70% of tumor cells showed immunoreactivity of ZEB2 in nuclei (6100). (F) Negative expression of ZEB2 was
observed in a HCC case (case 89, 6100). Representative sites with higher (inset,6400) magnification were shown. (G) The box plot shows the mean
staining intensity of cytoplasmic ZEB2 from HCC and peritumoral liver tissues (P,0.0001). (H) The box plot demonstrates the range of nuclear ZEB2
expression within each group (HCC, n=248; peritumoral liver tissue, n=248; P,0.0001).
doi:10.1371/journal.pone.0032838.g002
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clinical stage, vascular invasion, and relapse) were further
evaluated in multivariate analysis. Our result showed that
overexpression of ZEB2 in peritumoral liver tissues was an
independent prognostic factor for favorable patient overall survival
(hazard ratio, 0.572; 95%CI, 0.374–0.873, P=0.010; Table 3). Of
the other variables, serum AFP level (P,0.0001), tumor
multiplicity (P=0.021) and vascular invasion (P=0.008) were
evaluated as well independent prognostic factors for patients’
overall survival.
Correlations between expression of ZEB2 and E-cadherin
or Vimentin in HCC
Additional IHC staining of E-cadherin and Vimentin has been
performed on our HCC-TMA and thus, to analyze the potential
correlation between expression of ZEB2 and E-cadherin or
Vimentin in HCCs. Similarly, by utilizing the ROC curve
analysis, the cutoffs for high expression of E-cadherin and
Vimentin in HCC were defined when the cases with H score
above the value of 160 and 75, respectively. High expression of E-
cadherin and Vimentin were detected in 122/248 (49.2%) and
118/248 (47.6%) of HCCs, respectively (Figure S2). Further
correlation analysis showed that there was no statistically
significant correlation between cytoplasmic or nuclear expression
of ZEB2 and E-cadherin or Vimentin in our HCC cohort
(P.0.05, Fishers exact test).
Discussion
ZEB2 has been suggested to mediate EMT and disease
aggressiveness in various human cancers [14,24]. Previous studies
also showed increased levels of ZEB2 transcripts in association
with invasion and metastasis in cancers with advanced stages
[16,25,26]. However, the significance of ZEB2 expression in HCC
and its effect on prognosis of HCC are still unclear. Thus, we
performed the present large-scale study to investigate the
expression dynamics of ZEB2 in tumor and peritumoral liver
tissues and its clinicopathologic/prognostic significance in HCC
patients using high-throughput TMA and IHC.
In this current study, the antibody used was a polyclonal anti-
human ZEB2, which can detect an endogenous region of human
ZEB2. Our result indicated that the staining of ZEB2 in HCCs
predominantly displayed a cytoplasmic pattern, although nuclear
staining was also observed in a few cases. This was consistent with
the previous study, in which, Oztas [27] et al generated two anti-
ZEB2 antibodies, clones 1C6 and 6E5, and assessed their
immunoreactivity in a IHC study of cell lines and multiple tumor
tissue arrays, yielded the similar results. These findings suggest that
the observed expression pattern of ZEB2 by IHC was general to be
a cytoplasmic pattern, while the nuclear localization of ZEB2
could be observed in only a few tumors. Interestingly, in our study,
cytoplasmic expression pattern of ZEB2 was not only found in
HCC tissues but also observed in peritumoral liver tissues. Similar
findings were also documented in esophageal, gastric, colorectal
and ovarian cancers [27,28]. Moreover, the mean staining
intensity of ZEB2 in HCCs was significantly lower than those in
the peritumoral liver tissues. Consistent with our IHC findings, a
recent report also indicated that strong cytoplasmic expression of
ZEB2 could be detected in normal epithelial cells including
hepatocytes, kidney tubules, stomach glandular and colon surface
epithelium, and that ZEB2 appeared to be prevented from
translocating into nucleus in these tissues [27]. In addition,
cytoplasmic overexpression of ZEB2 in HCC tissues was found to
correlate with low serum AFP level, small tumor size and well
tumor differentiation, and negative correlation of overexpression
of cytoplasmic ZEB2 in PLTs and serum AFP level was also
observed. These data suggested that the up-regulated expression of
ZEB2 in tumor and peritumoral tissues of HCC might be a
protective role for ZEB2 against tumorigenesis. However, the
underlying mechanisms still need further to be clarified.
The most important finding of the present study was the
prognostic significance of cytoplasmic ZEB2 expression in HCC
and peritumoral liver tissues. In this study, overexpression of
cytoplasmic ZEB2 was associated closely with HCC patient longer
survival time as evidenced by univariate analysis in both tumor
and peritumoral liver tissues. Strikingly, HCC patients with ZEB2
overexpression in both tumor and peritumoral tissues have the
longest survival time among the subgroups of different ZEB2
expression status. Moreover, no significant association of ZEB2
expression and E-cadherin or Vimentin expression was found in
our HCC cohort. With regards to the role of ZEB2 in the
progression of human cancers, some of the results are totally
contradictory. On one hand, it has been reported that elevated
ZEB2 expression correlated positively with adverse patient survival
in breast, ovarian, kidney, oral and bladder cancers [14,15,16,17].
Also, ZEB2-mediated upregulation of EMT and tumor invasion
related genes, such as E-cadherin, vimentin and metalloproteases,
have been indicated [16]. On the other hand, ZEB2 was shown to
inhibit expression of cyclin D1 and be partly responsible for
hTERT repression [13,29]. In addition, downregulation of ZEB2
in HCC cell lines and cancers was found to be mediated by
aberrant promoter methylation [30]. Considering that ZEB2 takes
part in the TGF-b pathway and the effects of TGF-b on cell are
variable and depend on various factors including cell type and
physiological state of tissues [31,32], it is not very difficult for us to
understand that the function of ZEB2 and its underling
mechanism(s) to impact cancer progression may be tumor-type
specific. These data, collectively, might also provide a possible
explanation that in our present study, why expression of ZEB2 was
Figure 3. The cytoplasmic overexpression of ZEB2 in HCC
tissues inversely correlated with tumor differentiation. (A)
Negative expression of cytoplasmic ZEB2 was demonstrated in a
poorly-differentiated HCC case (case 68, 6100). (B) Overexpression of
cytoplasmic ZEB2 was observed in a well-differentiated HCC case (case
53), in which more than 95% of tumor cells showed immunoreactivity of
ZEB2 protein in cytoplasm (6100). Representative sites in HCC tissue
with higher (6200) magnification were shown.
doi:10.1371/journal.pone.0032838.g003
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Variables All cases Mean survival (months) Median survival (months) P value
Age (years) 0.329
#47.8* 123 52.8 72.0
.47.8 125 47.1 35.0
Sex 0.589
Male 220 50.6 NR
Female 28 49.7 40.0
HbsAg 0.743
Positive 216 50.4 40.0
Negative 32 45.6 30.0
AFP (ng/ml) 0.000
#20 119 64.7 NR
.20 129 36.6 25.0
Liver cirrhosis 0.836
Yes 179 48.9 38
No 69 50.5 40
Tumor size (cm) 0.000
#5 133 58.9 76.0
.5 115 40.3 24.0
Tumor multiplicity 0.000
Single 140 60.4 NR
Multiple 108 37.3 27.0
Differentiation 0. 085
Well-moderate 148 52.6 NR
Poor-undifferentiated 100 46.1 29.0
Stage 0.003
I-II 173 54.4 74.0
III -IV 75 36.4 24.0
Vascular invasion 0.000
Absent 170 58.0 NR
Present 78 30.5 20.0
Relapse 0.000
Absent 148 58.5 NR
Present 100 38.8 27
Cytoplasmic ZEB2 expression
Tumor tissues 0.026
Normal expression 98 41.8 27.0
Overexpression 150 53.8 72.0
Peritumoral liver tissues 0.001
Normal expression 130 42.5 28.0
Overexpression 118 57.6 NR
Nuclear ZEB2 expression
Tumor tissues 0.549
Normal expression 230 49.9 38.0
Overexpression 18 48.2 56.0
Peritumoral liver tissues 0.280
Normal expression 191 48.5 38.0
Overexpression 57 54.6 74.0
*Mean age; NR, not reached; HbsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein.
doi:10.1371/journal.pone.0032838.t002
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HCC tissues.
In our study, cytoplasmic ZEB2 overexpression in peritumoral
liver tissues was further evaluated as an independent factor of
favorable survival for HCC patients. We also found that
cytoplasmic expression in the peritumoral liver tissue is better
able to stratify cancer specific survival than expression in the
tumor tissue. To our best knowledge, few studies that focus on
peritumoral liver tissues on patient survival have been indicated.
Zhu et al [5] found that high expression of macrophage colony-
stimulating factor in peritumoral liver tissues was correlated with
poor survival after curative resection of HCC. Ezaki et al [33]
showed that higher peritumoral expression of thymidine phos-
phorylase was associated with a higher incidence of postoperative
recurrence in HCC. Also, Okamoto et al [34] reported that a
specific gene profile in peritumoral liver tissue could predict
multicentric occurrence or recurrence of HCC. In accordance
with previous study [13], our observations suggest that ZEB2 may
act as a tumor suppressor gene in HCC. Furthermore, we found
that ZEB2 overexpression was more frequently seen in peritu-
moral hepatocytes compared to HCC cells, which might provide a
more powerfully protective role to inhibit HCC growth. It might
provide a possible explanation for why ZEB2 expression in the
adjacent tissue better prognosticates than the expression in the
tumor tissue. Together with these data, the present study implies
that postoperative adjuvant therapies should target not only the
residual cancer cells, but also the soil to make it resistant to tumor
growth. Anyway, since majority of the previous studies was focus
on the expression status of ZEB2 in tumor tissues of different
human cancers, our data suggested, for the first time, a potential
role of ZEB2 expression in peritumoral liver tissues in tumor
development of HCC.
In summary, our results provide interesting and new informa-
tion that overexpression of cytoplasmic ZEB2 in HCC and
peritumoral liver tissues may be important in the acquisition of a
favorable phenotype, suggesting that overexpression of cytoplas-
mic ZEB2 by peritumoral liver tissues, as detected by IHC, may
predict the postoperative survival of patients with HCC, and it
might be a helpful criterion to optimize individual therapeutic
management.
Table 3. Cox multivariate analyses of prognostic factors on overall survival.
Variables Hazards ratio 95% CI P value
AFP, ng/ml (#20 v .20) 2.465 1.587–3.828 0.000
Tumor size, cm (#5 v .5) 1.383 0.929–2.057 0.110
Tumor multiplicity (single v multiple) 1.594 1.073–2.368 0.021
Stage (I–II v III–IV) 1.245 0.760–2.038 0.385
Vascular invasion (absent v present) 1.915 1.184–3.098 0.008
Relapse (absent v present) 1.281 0.862–1.904 0.221
Cytoplasmic expression of ZEB2
TT (normal v overexpression) 0.866 0.581–1.290 0.480
PLT (normal v overexpression) 0.572 0.374–0.873 0.010
CI, confidence interval; AFP, alpha-fetoprotein; TT, tumor tissue; PLT, peritumoral liver tissue.
doi:10.1371/journal.pone.0032838.t003
Figure 4. Kaplan-Meier survival analysis according to cytoplasmic ZEB2 expression in 248 patients with hepatocellular carcinoma
(log-rank test). (A) Cytoplasmic expression of ZEB2 in tumor tissues, probability of survival of all patients with HCC: normal expression of ZEB2, n=98;
overexpression of ZEB2, n=150 (P=0.026). (B) Cytoplasmic expression of ZEB2 in peritumoral liver tissues, probability of survival of all patients with
HCC: normal expression of ZEB2, n=130; overexpression of ZEB2, n=118 (P=0.001). (C) Comparison of overall survival according to a combined
cytoplasmic ZEB2 prognostic model (including tumorous and peritumoral expression): low risk, n=86; intermediate risk, n=95; high risk, n=67
(P=0.002).
doi:10.1371/journal.pone.0032838.g004
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Figure S1 The expression of ZEB2 in HCC and adjacent
liver tissues by Western blotting. Down-regulated expression
of ZEB2 was detected in 9/12 cases of HCC tissues compared to
adjacent liver tissues. T, HCC tissue; N, peritumoral liver tissue.
(TIF)
Figure S2 The expression patterns of E-cadherin and
Vimentin in HCC tissues by immunohistochemistry.
Overexpression of E-cadherin and Vimentin were shown in
representative cases of patient with HCC.
(TIF)
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